The drug services firm Evotec has acquired Central Glass Germany from the Japanese chemical maker Central Glass for 1 € (99 cents). The deal includes a facility in Halle/Westphalia, Germany, with a staff of 60 and “significant” reactor capacity, Evotec says. The plant will support clinical- and commercial-scale manufacturing of small- molecule drugs for Evotec customers. Evotec intends to make the facility its European center for active pharmaceutical ingredients for rare diseases.
That's a flamin' hot deal, so there must be some kind of problem with the plant? Or there is a plant to be named later?
A lot of deals like this include all of a facility’s debt along with the assets.
ReplyDeleteAPI for "rare" disease...............PR ploy.
ReplyDeletewhat difference does it make where API are made??
It might be that becuase it is for rare diseases a lot of API is not needed. Therefore, the facility might be a lot of smaller reactors and equipment, similar to a GMP pilot plant or GMP kilo lab arm of a larger manufacturer. The smaller scale focus could be the selling point. "We care about your small batches" DISCLAIMER: I haven't looked up the site and am just speculating.
Delete